Development of Computational Pipeline for Right Ventricular Hemodynamic Single-Beat Analysis

Gyeongtae S. Moon; Paul J. Scheel; Maggie Montovano; Milan Kaushik; Cole Buchanan; Samuel H. Friedman; Rebecca Vanderpool; M. Imran Aslam; Ryan J. Tedford; Paul M. Hassoun; Vivek P. Jani; Steven Hsu

doi:10.1101/2025.06.01.25328762

ABSTRACT

Background Load-independent indices of right ventricular (RV) dysfunction aid in the prognosis of patients with pulmonary hypertension (PH), but their acquisition remains difficult. This study aimed to develop a novel computer vision artificial intelligence-based pipeline that can estimate load-independent RV functional indices using screenshots of the RV pressure-time waveform from a standard clinical right heart catheterization (RHC).

Methods Prospectively collected clinical data and research-grade pressure-volume-time data were collected from 76 patients from three centers. Patients were referred for RHC for known or suspected PH. Thirty-nine patients from one center were used for internal development, with external validation performed on the remaining 37 patients from two independent centers. A MATLAB-based computational pipeline was developed to predict RV pressure-volume (P-V) loop and extract load-independent RV indices using image processing and single-beat analysis. Agreement with gold-standard single-beat analysis was assessed via Bland-Altman analysis, concordance correlation coefficient (CCC), and Pearson correlation coefficient. Kaplan-Meier survival analysis, Cox regression analysis, and K-means clustering were performed to evaluate prognostic value.

Results The average age of the derivation cohort was 57±12 years. Strong concordance was observed between the novel and gold-standard methods for end-systolic elastance (Ees, R=0.96, CCC=0.58), effective arterial elastance (Ea, R=0.97, CCC=0.88), end-diastolic elastance (Eed, R=0.87, CCC=0.47), and Ees/Ea ratio (R=0.93, CCC=0.71). Agreement was validated with the external cohort. Prognostic analyses showed that pipeline-derived Ea (HR: 2.09 [1.04, 4.20]) and Ees/Ea (HR: 0.27 [0.08, 0.87]) were significant predictors of clinical outcomes. Cluster analysis identified two RV sub-phenotypes with distinct hemodynamic features, with the group exhibiting higher Ea (1.05±0.27 vs. 0.41±0.19 mmHg/mL, p<0.0001) and lower Ees/Ea (0.37±0.15 vs. 0.76±0.40 mmHg/mL, p=0.0002) demonstrating worse outcomes.

Conclusion We have developed a novel computational pipeline tool that digitizes and generates single-beat estimates of RV-pulmonary arterial coupling from an image of the RV pressure waveform. Its output correlates with single-beat methods and predicts clinical outcomes.

Competing Interest Statement

Dr. Tedford reports no disclosures relevant to this manuscript. Dr. Tedford is Deputy Editor for the Journal of Heart and Lung Transplantation. He reports general disclosures to include consulting relationships with and receiving honorarium/consulting fees from Abbott, Acorai, Adona, Aria CV Inc., Acceleron, Alleviant, Boston Scientific, CVRx, Cytokinetics, Endotronix, Edwards LifeSciences, Fauna Bio, Gradient, Imbria, Medtronic, Merck, Morphic Therapeutics, Pulmovant, Restore Medical, Tempus AI, and United Therapeutics. Dr. Tedford serves on steering committees for Abbott, Edwards, Endotronix, Gradient, Merck and Tempus AI as well as a research advisory board for Abiomed. Dr. Aslam reports consulting disclosures with Teleflex and Gradient. The other authors do not report any potential conflict of interest, real or perceived.

Funding Statement

This study was funded by NIH NHLBI R01HL172830.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of Johns Hopkins University gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

Dr. Tedford reports no disclosures relevant to this manuscript. Dr. Tedford is Deputy Editor for the Journal of Heart and Lung Transplantation. He reports general disclosures to include consulting relationships with and receiving honorarium/consulting fees from Abbott, Acorai, Adona, Aria CV Inc., Acceleron, Alleviant, Boston Scientific, CVRx, Cytokinetics, Endotronix, Edwards LifeSciences, Fauna Bio, Gradient, Imbria, Medtronic, Merck, Morphic Therapeutics, Pulmovant, Restore Medical, Tempus AI, and United Therapeutics. Dr. Tedford serves on steering committees for Abbott, Edwards, Endotronix, Gradient, Merck and Tempus AI as well as a research advisory board for Abiomed. Dr. Aslam reports consulting disclosures with Teleflex and Gradient. The other authors do not report any potential conflict of interest, real or perceived.
Funding and Disclosures: NHLBI R01 HL172830 (S.H.)